The positive Chinese phase III data increases the probability of success for Ris-Rez but does not change near-term financials. Traders should watch for the upcoming global EMBOLD SCLC-301 readout (expected next year) as a more material catalyst for GSK's valuation. No immediate trading action warranted.
Price Chart
Executive Summary
GSK announced positive phase III overall survival data for its B7-H3-targeted ADC risvutatug rezetecan (Ris-Rez) in advanced or relapsed small-cell lung cancer from the Chinese ARTEMIS-008 trial. This is the first positive phase III OS data for any B7-H3-targeted ADC, de-risking GSK's pipeline and supporting its global development program. The data is from a China-only trial by licensor Hansoh Pharma; GSK's own global phase III EMBOLD SCLC-301 results are expected next year.
Key Facts
- ARTEMIS-008 phase III trial met primary endpoint of overall survival in advanced/relapsed SCLC, with statistically significant and clinically meaningful improvement vs topotecan.
- First positive phase III overall survival data for a B7-H3-targeted ADC in any tumour type.
- GSK holds exclusive global rights to develop Ris-Rez outside mainland China, Hong Kong, Macau and Taiwan.
- Global phase III EMBOLD SCLC-301 trial in relapsed ES-SCLC with pivotal data expected next year.
- Ris-Rez has received FDA Breakthrough Therapy Designation, EMA PRIME Designation, and orphan drug designations from FDA, EMA, and Japan.
Financial Impact
Positive phase III OS data de-risks Ris-Rez and strengthens GSK's oncology pipeline; potential peak sales in SCLC if approved but no near-term revenue impact.
Risk Factors
- Clinical and regulatory risk for global phase III trials and eventual approvals.
- Competition from other B7-H3-targeted therapies (e.g., Daiichi Sankyo's DS-7300, AbbVie's ABBV-400) and existing SCLC treatments (tarlatamab, lurbinectedin).
- Commercialization risk and pricing/reimbursement challenges in lung cancer.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-006601 |
| Document: 0001654954-26-006601-index-headers.html | 0001654954-26-006601 |
| Document: 0001654954-26-006601-index.html | 0001654954-26-006601 |
| Document: 0001654954-26-006601.txt | 0001654954-26-006601 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 6-K | $50.01 $50.22 | ▲ +0.42% | ▼ −0.40% | $47.03 (−5.96%) |
Sep 14, 2026 18d ago | 6-K | $50.05 $51.08 | ▲ +2.06% | ▲ +1.95% | $47.03 (−6.03%) |
Sep 14, 2026 18d ago | 6-K | $50.05 $51.08 | ▲ +2.06% | ▲ +1.95% | $47.03 (−6.03%) |
Sep 11, 2026 21d ago | 6-K | $48.13 $50.22 | ▲ +4.34% | ▲ +4.56% | $47.03 (−2.29%) |
Sep 10, 2026 22d ago | 6-K | $48.12 $51.06 | ▲ +6.11% | ▲ +6.61% | $47.03 (−2.27%) |
Sep 10, 2026 22d ago | 6-K | $48.12 $51.06 | ▲ +6.11% | ▲ +6.61% | $47.03 (−2.27%) |
Sep 1, 2026 4w ago | 6-K | $50.66 $48.63 | ▼ −4.01% | ▼ −4.09% | $47.03 (−7.17%) |
Sep 1, 2026 4w ago | 6-K | $50.66 $48.63 | ▼ −4.01% | ▼ −4.09% | $47.03 (−7.17%) |
Aug 26, 2026 5w ago | 6-K | $51.43 $50.44 | ▼ −1.92% | ▼ −1.80% | $47.03 (−8.56%) |
Aug 24, 2026 5w ago | 6-K | $51.78 $50.25 | ▼ −2.95% | ▼ −3.42% | $47.03 (−9.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access